Ascendis Pharma A/S
F:A71
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Ascendis Pharma A/S
F:A71
|
DK |
|
First Business Financial Services Inc
F:45D
|
US |
|
CTS Corp
F:XT1
|
US |
|
National Energy Services Reunited Corp
NASDAQ:NESR
|
US |
|
R
|
RH
XMUN:RS1
|
US |
|
A
|
Atoss Software AG
DUS:AOF
|
DE |
|
E
|
Eastman Chemical Co
F:EAC
|
US |
|
G
|
Global Power Synergy PCL
SET:GPSC
|
TH |
|
D
|
Dexcom Inc
XMUN:DC4
|
US |
|
I
|
I-Tail PCL Corp
SET:ITC
|
TH |
Wall St Price Targets
A71 Price Targets Summary
Ascendis Pharma A/S
According to Wall Street analysts, the average 1-year price target for A71 is 245.98 EUR with a low forecast of 207.63 EUR and a high forecast of 306.79 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is A71's stock price target?
Price Target
245.98
EUR
According to Wall Street analysts, the average 1-year price target for A71 is 245.98 EUR with a low forecast of 207.63 EUR and a high forecast of 306.79 EUR.
What is the Revenue forecast for Ascendis Pharma A/S?
Projected CAGR
24%
Over the last 12 years, the compound annual growth rate for Revenue has been 35%. The projected CAGR for the next 8 years is 24%.
What is the Gross Profit forecast for Ascendis Pharma A/S?
Projected CAGR
25%
The compound annual growth rate for Gross Profit over the next 8 years is 25%.
